Overview
- Editors:
-
-
Karen L. Furie
-
Massachusetts General Hospital, Boston, USA
Harvard Medical School, Boston, USA
-
Peter J. Kelly
-
Massachusetts General Hospital, Boston, USA
Mater Misericordiae University Hospital, Dublin, Ireland
University College, Dublin, Ireland
Access this book
Other ways to access
Table of contents (17 chapters)
-
Front Matter
Pages i-xiii
-
- Eric E. Smith, Walter J. Koroshetz
Pages 1-18
-
- John Sims, Walter J. Koroshetz
Pages 19-33
-
- Donald M. Lloyd-Jones, Christopher J. O’Donnell
Pages 35-50
-
- Mehmet Akif Topcuoglu, Ferdinando S. Buonanno, Peter J. Kelly
Pages 51-78
-
- Maria Wormack, Ferdinando S. Buonanno
Pages 79-86
-
- Mehmet Akif Topcuoglu, Karen L. Furie
Pages 87-103
-
-
- Dominick J. H. McCabe, Peter J. Kelly, J. Philip Kistler
Pages 117-137
-
- MingMing Ning, Karen L. Furie, Jan L. Shifren, J. Philip Kistler
Pages 139-149
-
- Karen L. Furie, Stelios M. Smimakis, Walter J. Koroshetz, J. Philip Kistler
Pages 151-165
-
-
- Karen L. Furie, Aneesh B. Singhal, J. Philip Kistler
Pages 187-198
-
- Stelios M. Smirnakis, Walter J. Koroshetz
Pages 199-225
-
- Raul G. Nogueira, Aneesh B. Singhal
Pages 227-242
-
- David M. Greer, Ferdinando S. Buonanno
Pages 243-256
-
- Rachel Farrell, Peter J. Kelly
Pages 257-278
-
- Peter J. Kelly, Karen L. Furie
Pages 279-301
-
Back Matter
Pages 303-310
About this book
Despite major advances in the understanding of stroke mechanisms that have occurred over the past quarter century, stroke continues to rank among the leading causes of death and disability worldwide. Although currently it may be difficult to believe, early doubts were expressed as to whether inter ventions in risk factors for either coronary disease or stroke would actually lead to a reduction in the incidence of these disorders. However, large clini cal trials in hypertension, carotid disease, atrial fibrillation, and antithrombotic and antiplatelet therapies have effectively demonstrated the efficacy of these targeted interventions in reducing stroke incidence. More recently, after earlier uncertainty regarding the role of elevated lipids as a risk factor for stroke, clinical trials of the statins have also demonstrated a significant reduction in the incidence of ischemic stroke. However, as em phasized in Handbook of Stroke Prevention in Clinical Practice, despite these gains and the initial decline in stroke incidence that did occur in the 1960s and 1970s, the incidence of stroke disappointingly has failed to show a fur ther significant decline since that time. The editors of Handbook of Stroke Prevention in Clinical Practice raise the very important question of whether recognized strategies for stroke preven tion have been widely or effectively implemented. They correctly empha size the critical importance of identifying the mechanism of stroke in each patient so as to properly direct prevention and treatment. As Dr.
Reviews
"As a comprehensive yet succinct source of information to the provider with tables and graphs summarizing key points of each chapter, this book will be invaluable in providing recommendations about modifying stroke risk factors. 4 Stars!" -Doody's Health Sciences Book Review Journal
"...a very comprehensive analysis of both common and less common causes of stroke...strongly recommend(ed)." - Age and Ageing
"...undoubtedly a 'must have' part of the clinical pharmacist's library...informative and pertinent to the management of this growing population of at-risk patients." - The Annals of Pharmacology
"...offers a succinct analysis of evidence-based stroke management and might easily serve as a guide for any physician who routinely treats patients with cerebrovascular disease." - Texas Heart Institute Journal
"...an excellent guide through state-of-the-art information concerning risk factors and available intervention strategies in patients with stroke." - J. Neuosurg
